Stay updated on DSP-5336 in Relapsed AML Clinical Trial
Sign up to get notified when there's something new on the DSP-5336 in Relapsed AML Clinical Trial page.

Latest updates to the DSP-5336 in Relapsed AML Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov site revision label changed from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check8 days agoChange DetectedThe study record for the Phase 1/2 enzomenib trial is now displayed, including its eligibility criteria, study design, outcome measures, and recruiting locations.SummaryDifference100%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check28 days agoChange DetectedA site-wide notice announces NIH website updates and a terminology transition from “Artificial Intelligence” to “Super Intelligence.” The study record remains inaccessible behind a 403 error.SummaryDifference1%

- Check35 days agoChange DetectedThe ClinicalTrials.gov page remains a 403 Forbidden error page, with its displayed site revision changing from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check42 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1; the page continues to display a 403 error.SummaryDifference0.2%

Stay in the know with updates to DSP-5336 in Relapsed AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DSP-5336 in Relapsed AML Clinical Trial page.